The Denko Lab studies the role of the tumor microenvironment on malignant progression and resistance to therapy. Specifically, we study tumor hypoxia and its impact on metabolism, mitochondrial function, resistance to radiotherapy and immunotherapy. We have developed the used o mitochondrial inhibitors as a means of reducing tumor hypoxia resulting in increased tumor sensitivity. We have a repurposed FDA-approved drug in clinical trial for the treatment of NSCLC, and are developing second generation molecules with reduced normal tissue toxicities.